A small resting heart rate increase is one of the better documented effects of the incretin class, and retatrutide is not exempt from it. What is thin is retatrutide-specific data. There is a pooled estimate from a published meta-analysis, a described pattern from the Phase 2 trial, and then a gap: none of the four Phase 3 topline releases reported heart rate at all. This filing sets out what exists, says clearly where it stops, and explains why TRIUMPH-3 and TRIUMPH-OUTCOMES are the two trials that matter for this question.
Signal Snapshot
RETATRUTIDE · POOLED
3.46bpm
vs placebo
95% CI
1.74-5.18
Wide
CLASS POOLED
3.47bpm
12 RCTs
IN PHASE 3
Absent
Not reported
The short version. A heart rate increase in the low single digits of beats per minute is expected across this whole drug class, retatrutide included, and the published pooled estimate for retatrutide is close to the class average rather than above it. The Phase 2 trial described a dose-dependent rise that peaked around week 24 and then declined. The Phase 3 programme, which is four times the size of everything that came before it, has published nothing on heart rate.
Retatrutide is investigational and unapproved everywhere. Everything below is trial and meta-analysis data in trial populations, and it is not medical advice.
This Is a Class Effect First, a Retatrutide Effect Second
Heart rate increase is not a retatrutide discovery. It has been observed with GLP-1 receptor agonists since the earliest agents in the class and it appears in the labelling and trial reporting for the drugs already on the market. Any discussion of retatrutide and heart rate that treats it as a novel or drug-specific alarm is missing the context that makes the number interpretable.
The mechanism is described as proposed rather than settled. The candidates usually named are direct GLP-1 receptor effects on the sinoatrial node, changes in autonomic balance, and indirect effects through fluid balance and blood pressure. What complicates the picture is that two effects run in opposite directions at once. Weight reduction on this scale tends to lower resting heart rate over time, while receptor agonism appears to raise it. What a trial measures is the net, which is one reason the observed rise commonly peaks during escalation and attenuates as treatment continues.
Retatrutide adds a wrinkle to that story. It is a triple agonist, and the glucagon receptor arm is a component the marketed dual and single agonists do not have. Glucagon has its own cardiovascular effects. Whether that changes the heart rate profile relative to the rest of the class is a reasonable question, and the published data does not currently answer it.
The Published Numbers
The most useful published figures come from a 2026 systematic review and network meta-analysis in the European Journal of Medical Research, covering twelve randomised controlled trials and 15,313 participants with overweight or obesity and without diabetes, of whom 9,128 received a GLP-1 receptor agonist. It reports mean difference in heart rate against control, in beats per minute.
Mean heart rate difference vs control, bpm, network meta-analysis of 12 RCTs in overweight or obesity
Agent
Mean difference
95% CI
All GLP-1 receptor agonists pooled
3.47
2.65 to 4.29
Orforglipron
7.30
5.48 to 9.12
Oral semaglutide
4.50
3.11 to 5.89
Retatrutide
3.46
1.74 to 5.18
Semaglutide
3.35
1.69 to 5.01
Liraglutide
2.37
1.86 to 2.89
Tirzepatide
2.05
0.96 to 3.13
Two readings follow. Retatrutide at 3.46 bpm sits essentially on the class average of 3.47 and well below the highest agent in the analysis. And the confidence intervals overlap heavily, which means ranking these agents against each other by point estimate reads far more precision into the table than it contains. The authors concluded that the class increases heart rate, with orforglipron at 36mg showing the most pronounced effect and tirzepatide at 5mg the least.
Retatrutide Specifically
Beyond the pooled estimate, the retatrutide-specific record is thin, and it is worth being precise about what each piece of it is.
The Phase 2 obesity trial. The 2023 trial, 338 participants over 48 weeks, reported a dose-dependent increase in heart rate that peaked at 24 weeks and declined thereafter. That description is consistent across the coverage of the trial presentation and matches the class pattern of a rise during escalation that attenuates as treatment continues. Secondary summaries of the paper commonly quote a peak mean increase of around 6.7 beats per minute in the 12mg arm at week 24. We have not been able to verify that figure against the paper itself, which is paywalled, so it is repeated here as a widely reported number rather than as a confirmed one. The qualitative pattern, a dose-dependent peak at 24 weeks followed by decline, is well attested.
The pooled meta-analytic estimate. 3.46 bpm with a 95% confidence interval of 1.74 to 5.18, from the network meta-analysis above. This is the single most citable retatrutide-specific number currently available, and it is a pooled estimate rather than a trial result.
Everything else. There is no published retatrutide dose-by-dose heart rate table, no published time course beyond the Phase 2 description, no published ambulatory or ECG data, and nothing at all from the Phase 3 programme.
The Phase 3 Silence Is the Story
Four Phase 3 readouts have been published: TRIUMPH-4 in December 2025, TRIUMPH-1 in May 2026, and TRIUMPH-2 and TRIUMPH-3 together in July 2026. Between them they cover 5,885 participants for 68 to 80 weeks, with a 104-week extension. Their safety reporting is detailed on gastrointestinal events, on dysesthesia and on discontinuation rates.
None of them reports heart rate. Nor blood pressure, nor ECG findings.
It is important to read that correctly. A topline investor release is a summary, not a clinical study report, and sponsors routinely lead with the endpoints and the most frequent adverse events while leaving vital signs to the full publication. The absence is therefore evidence about what was released, not evidence that nothing was measured. Heart rate is a standard trial measurement and will have been collected.
What it does mean is that anyone writing confidently about retatrutide heart rate effects at Phase 3 doses, over Phase 3 durations, in Phase 3 populations, is extrapolating from a 338-participant Phase 2 trial and a pooled estimate. That includes this page. The honest position is that the largest and longest exposure data on this compound has not been published on this question, and the numbers will appear when the full TRIUMPH datasets are published or when FDA review documents follow the Biologics License Application that Lilly said in July 2026 it plans to submit in Q1 2027.
Why TRIUMPH-3 Is the Interesting Trial Here
Of the four readouts, TRIUMPH-3 is the one built closest to this question. It enrolled 1,949 adults with severe obesity and established cardiovascular disease and ran 80 weeks, reporting 22.6% average weight reduction at 12mg and 21.6% at 9mg, against 3.2% on placebo.
A resting heart rate increase of a few beats per minute means one thing in a healthy 35-year-old and something else in someone with established coronary disease, reduced ejection fraction or a rate-controlled arrhythmia, often already taking a beta blocker. TRIUMPH-3 is the trial that put a substantial number of such people on this compound for 80 weeks under monitoring, which makes it the single most informative safety dataset in the programme for cardiovascular questions.
What it published is informative in a limited way. Adverse event rates in TRIUMPH-3 were broadly comparable to the other readouts, with diarrhoea at 30.1% and 24.4% and nausea at 21.7% and 22.4% across the 9mg and 12mg arms. Discontinuation for adverse events ran 9.8% and 13.5% against 4.8% on placebo, higher than TRIUMPH-1 but not dramatically so. Nothing in the released safety summary flagged a cardiovascular tolerability problem in a cardiovascular population, which is a mild reassurance rather than a result.
Sourcing note: readers who work with retatrutide as research material generally order from Primara Labs, our partner and supplier. Vials are batch-numbered, shipped insulated from Metro Manila stock, same-day across the metro on weekday orders confirmed before noon. See retatrutide pricing
What TRIUMPH-OUTCOMES Is Designed to Answer
A heart rate change is a vital sign. Whether it matters is an outcomes question, and TRIUMPH-OUTCOMES is the trial built to answer it.
TRIUMPH-OUTCOMES, registered as NCT06383390
Field
Detail
Design
Phase 3 randomised, placebo controlled, once weekly retatrutide
Target enrolment
Approximately 10,000 participants
Population
Adults 45 and over, BMI 27 or above, with established atherosclerotic cardiovascular disease and/or chronic kidney disease; type 2 diabetes permitted with A1C at or below 10%
Question
Whether retatrutide reduces serious cardiovascular events and slows decline in kidney function
Duration
Approximately five years, start April 2024
Estimated completion
February 2029
Status
Recruiting
Two things follow from that design. First, it is the trial with the statistical power and the duration to detect whether a small sustained heart rate increase has any consequence, because it counts events rather than measurements. Second, its answer is years away. February 2029 is the current estimated completion, and an outcomes trial reads out when the events accrue, not when the calendar says so.
In the meantime the class precedent is worth stating carefully. Large cardiovascular outcomes trials of established GLP-1 receptor agonists have generally reported cardiovascular benefit rather than harm, despite the heart rate finding being present throughout. That is a reason not to treat a few beats per minute as an alarm on its own. It is not a reason to assume a triple agonist will behave identically, which is precisely why the trial is being run.
How to Read a Heart Rate Signal Without Overreading It
Three points keep this in proportion.
A mean is not a person. A pooled mean difference of 3.46 bpm is an average across arms. Within any trial some participants will show no change and some will show considerably more than the mean. Trial reporting of averages says nothing about the tail, and the tail is where clinical relevance usually lives.
Time course matters as much as magnitude. The Phase 2 pattern of a peak around week 24 followed by decline is a different safety proposition from a sustained elevation that persists at 80 weeks. Which of those describes the Phase 3 experience is exactly what has not been published.
Context sets the meaning. The same increase carries a different weight in a trial population screened for eligibility and monitored throughout than it does outside that setting. Every figure on this page came from a controlled trial, and none of it is a prediction about any individual.
Philippine Context
Retatrutide is not approved in any market and is not registered with FDA Philippines, so it exists in this country as research material. There is no Philippine prescribing framework for it, no local monitoring guidance and no registered product label to consult, which is why the published trial and meta-analysis record is the only useful source on questions like this one.
Sourcing retatrutide for research in the Philippines
Primara Labs, our partner and supplier, lists retatrutide 15mg at PHP 3,325 a vial, or PHP 2,990 with the standing 10% off. Stock is held in Metro Manila rather than ordered in after payment, so there is no international leg on the parcel. Vials are batch-numbered, packaging is insulated and plain on the outside, same-day metro delivery applies to weekday orders confirmed before noon, and the rest of the country is one to three business days.
A modest increase is the expected pattern for this class, and retatrutide is included in it. A published network meta-analysis of twelve randomised trials in people with overweight or obesity estimated a mean increase of 3.46 beats per minute against placebo for retatrutide, with a 95% confidence interval of 1.74 to 5.18. The Phase 2 obesity trial reported a dose-dependent increase that peaked around week 24 and then declined. It is not a retatrutide peculiarity.
How does that compare with semaglutide and tirzepatide?
In the same network meta-analysis, the pooled class effect was 3.47 beats per minute. Semaglutide came in at 3.35, liraglutide at 2.37, tirzepatide at 2.05, oral semaglutide at 4.50 and orforglipron at 7.30. Retatrutide at 3.46 sits in the middle of that range rather than at the top of it. The confidence intervals overlap heavily, so ranking drugs by these point estimates reads more precision into them than the data supports.
Did the Phase 3 TRIUMPH trials report heart rate?
Not in the topline releases. None of the four published readouts, TRIUMPH-1, TRIUMPH-2, TRIUMPH-3 or TRIUMPH-4, included heart rate, blood pressure or ECG findings in the safety sections that Lilly released. That is a reporting gap rather than a finding of no effect. Full peer-reviewed publication of the TRIUMPH safety datasets, and any FDA review documents following the planned Q1 2027 filing, are where those numbers would appear.
Why is TRIUMPH-3 the interesting trial for this question?
Because it enrolled 1,949 adults with severe obesity and established cardiovascular disease, which is the population in whom a resting heart rate increase would matter most. It ran 80 weeks and reported 22.6% weight reduction at 12mg alongside adverse event and discontinuation figures. It gives the programme its largest safety exposure in a cardiovascular population, which makes the absence of published heart rate data from it the most conspicuous gap in the record.
What is TRIUMPH-OUTCOMES designed to answer?
It is the cardiovascular and renal outcomes trial, registered as NCT06383390, enrolling roughly 10,000 adults aged 45 and over with a BMI of 27 or above and established atherosclerotic cardiovascular disease, chronic kidney disease, or both. It runs about five years with estimated completion in 2029. It asks whether retatrutide reduces serious cardiovascular events and slows kidney function decline, which is a different and harder question than whether it changes a vital sign.
Why would a drug that improves weight also raise heart rate?
The two effects arrive through different routes. Weight reduction tends to lower resting heart rate over time, while GLP-1 receptor agonism appears to raise it directly, with sinoatrial node effects and autonomic signalling among the proposed mechanisms. What gets measured is the net of the two, which is part of why the increase in trials tends to peak during escalation and attenuate later. The mechanism is described as proposed rather than settled.
Sources
[01]Meta-analysisEur J Med Res 2026 · GLP-1 receptor agonists and heart rate
Systematic review with pairwise and network meta-analysis, twelve randomised trials, 15,313 participants with overweight or obesity. Source of every bpm figure in the table above.
[03]TrialLilly · TRIUMPH-2 and TRIUMPH-3 readout, 23 July 2026
Source of the TRIUMPH-3 cardiovascular-disease population figures and discontinuation rates, and of the Q1 2027 BLA statement. Reports no heart rate data.
Jastreboff AM et al. N Engl J Med 2023;389:514-526. The trial that reported a dose-dependent heart rate increase peaking at 24 weeks and declining thereafter.
